mortality/aging
• about half die during embryogenesis, no time of lethality provided
• survivors appear normal at 4 and 12 months of age
|
cellular
• MEFs fail to arrest in G1 48 h after doxorubicin treatment and instead continue to proliferate
|
• in MEFs 48 h after doxorubicin treatment
|
immune system
• spleen cells fail to arrest in G1 48 h after doxorubicin treatment
|
homeostasis/metabolism
• MEFs and spleen cells fail to arrest in G1 48 h after doxorubicin treatment
• an increase in apoptosis is not seen in MEFs 48 h after doxorubicin treatment unlike in controls
|